Skip to main content
Drug Development
Our Pipeline
Evaluation Pipeline
Inaphaea BioLabs
Therapeutic areas
Partnering
Useful Links
News
Investors
Regulatory News
AIM Rule 26
Annual and Half Yearly Reports
Admission Document & Articles
Shareholder communications
Investments Calculator
Share Alerts
Share Series
Share price look-up
Analyst Research
About us
Board of Directors and Management Team
Strategy and Vision
How we work
Working with us
Collaborative Pipeline
Contact us
Search
News
Breadcrumb
News
Category
Articles
Events and presentations
News
Press releases
Videos and audiocasts
News
ValiRx appoints permanent Chief Scientific Officer
31 Jan 2023
News
ValiRx signals launch of new strategy with Nottingham laboratories
31 Jan 2023
Videos and audiocasts
Question and Answer Videocast
26 Jan 2023
Articles
ValiRx quarterly Q&A webinar: key questions answered
20 Jan 2023
Articles
Meet the ValiRx team: Dr Kevin Cox
18 Jan 2023
Articles
Accelerating early stage, academic innovation: the Cytolytix story so far
4 Jan 2023
News
ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment
15 Dec 2022
Videos and audiocasts
ValiRx Q&A Live Webinar Held on 13th December 2022
14 Dec 2022
News
ValiRx to host live Q&A shareholder webinar
7 Dec 2022
News
ValiRx attends Biotech Outsourcing Strategies 2022
21 Nov 2022
News
ValiRx CEO introduces Cytolytix at London South East webinar
9 Nov 2022
Videos and audiocasts
LSE Investor Presentation Introducing Cytolytix
9 Nov 2022
News
ValiRx attends Bio-Europe 2022
26 Oct 2022
News
ValiRx signs IP license agreement with King's College London to progress triple negative breast cancer treatment
24 Oct 2022
Pagination
First page
First
Previous page
Previous
Page
1
Current page
2
Page
3
Page
4
Page
5
Next page
Next
Last page
Last